Serum Visfatin Increases With Progressive β-Cell Deterioration

López‐Bermejo, Abel; Chico-Julià, Berta; Fernández-Balsells, Mercè; Recasens, M; Esteve, Eduardo; Casamitjana, Roser; Ricart, Wifredo; Fernández-Real, José Manuel

doi:10.2337/db06-0259

Cited by 195 publications

(197 citation statements)

References 20 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…It has been demonstrated that plasma visfatin concentrations are inversely correlated to progressive ␤-cell deterioration in patients with type 1 or type 2 diabetes (15). The present data argue against an assumption that altered pancreatic insulin secretion has contributed to reduced plasma visfatin in GDM because insulin plasma concentrations were comparable in fasting conditions.…”

Section: Measurement Of Visfatincontrasting

confidence: 49%

Visfatin Response to Glucose Is Reduced in Women With Gestational Diabetes Mellitus

et al. 2007

View full text Add to dashboard Cite

T he insulin-mimetic adipocytokine visfatin has been associated with insulin resistance in some studies and is regulated by glucose. We hypothesized that glucose-induced changes in plasma visfatin are different in women with gestational diabetes mellitus (GDM). Plasma visfatin concentrations were studied in 10 women with GDM and 10 age-matched healthy women, in pregnancy weeks 24 -28, during a standard oral glucose tolerance test (OGTT). Women with GDM had lower systemic visfatin concentrations than control subjects (1.9 Ϯ 0.8 vs. 5.2 Ϯ 4.4 ng/ml, respectively, P Ͻ 0.05), which were associated with fasting glucose (P Ͻ 0.05). The glucose-induced increase in visfatin over baseline was smaller in women with GDM, with an area under the curve of 409 Ϯ 106 vs. 780 Ϯ 345 ng ⅐ ml Ϫ1 ⅐ min Ϫ1 in control subjects (P Ͻ 0.05). Reduced glucose-induced increases in circulating visfatin may be associated with impaired glucose tolerance in women with GDM.Women with GDM are at increased risk for developing type 2 diabetes; however, the pathophysiology is still poorly understood. Nonetheless, a variety of abnormalities that are also found in patients with type 2 diabetes are seen early in women in GDM (1). Among the factors that might contribute to altered glucose handling are changes in adipocytokines. For example, plasma adiponectin concentrations are lowered (2), and leptin and resistin persistently increased after delivery in women with GDM and are associated with hyperglycemia and insulin resistance (3,4).The adipocytokine visfatin has been reported to mimic actions of insulin by activating the insulin signal transduction pathway through binding to the same receptor (5). Systemic visfatin concentrations are acutely regulated by glucose and insulin (6) and elevated in patients with insulin resistance, obesity, and diabetes, as well as by rosiglitazone treatment (7-11).In an effort to address the question whether plasma visfatin regulation is altered in women with GDM, we have studied its concentration during pregnancy weeks 24 -28 and compared it with that of matched healthy pregnant women during a standard OGTT. RESEARCH DESIGN ANDMETHODS -Ten women with GDM (aged 33 Ϯ 2 years) diagnosed during pregnancy weeks 24 -28 were invited to participate in the study. GDM was defined as two or more of the following criteria: fasting morning plasma glucose after a minimum of 3 days of unrestricted diet and unlimited physical activity Ն5.3 mmol/l, 1-h postload 75-g glucose value Ն10.0 mmol/l, or 2-h postload glucose value Ն8.6 mmol/l. As control subjects, age-matched (34 Ϯ 1 years) pregnant women with normal OGTT were included.Inclusion criteria were signed informed consent, absence of a clinically relevant illness, normal findings in the medical history and physical examination except for GDM, and normal laboratory values. Subjects were excluded if any clinically relevant abnormality was found as part of the screening or in any of the laboratory tests including circulating antiinsulin antibodies and anti-islet cell antibodies. No subj...

show abstract

Section: Measurement Of Visfatincontrasting

confidence: 49%

Visfatin Response to Glucose Is Reduced in Women With Gestational Diabetes Mellitus

et al. 2007

View full text Add to dashboard Cite

show abstract

“…They also reported increased visfatin concentrations with worsening of glucose tolerance. Similarly, (4,5) reported increased circulating visfatin in patients with Type 2 DM, whereas another study (6) found that Type 2 diabetic patients showed decreased plasma visfatin concentrations. Circulating visfatin levels are reduced after weight loss in obese subjects (16), yet, in contrast, another study (17) found that weight loss has an increasing effect on visfatin concentrations.…”

Section: Discussionmentioning

confidence: 93%

Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester

Aktürk

Altınova

Mert

et al. 2008

J Endocrinol Invest

View full text Add to dashboard Cite

ABSTRACT. Our aim is to investigate visfatin concentration and its relationship to glycated hemoglobin (HbA 1c ), insulin resistance, lipid parameters, and neonatal birth weight in women with gestational diabetes mellitus (GDM). In our study group, there were 47 women with GDM and 31 women with normal glucose tolerance (NGT) between 33-39 weeks of gestation. Plasma visfatin levels were significantly decreased in pregnant women with GDM compared to those with NGT (p=0.001). Homeostasis model assessmentinsulin resistance (HOMA-IR) levels were higher in the GDM group than in the NGT group (p=0.006). In all subjects, plasma visfatin levels were negatively correlated with HOMA-IR, post-prandial blood glucose, triglycerides, and VLDL cholesterol (p<0.05). We did not observe any statistically significant correlation between the plasma visfatin levels and the selected parameters in the GDM group, but in the NGT group plasma visfatin levels were negatively correlated with HOMA-IR (r=-0.36, p=0.04). There was no correlation between visfatin concentrations and fetal birth weight in either group (p>0.05). By regression analysis, having GDM was found to be the only significant determinant (t=3.5, p=0.001) of visfatin concentration (R=0.39, r 2 =0.15). We conclude that women with GDM have significantly decreased visfatin concentrations in the third trimester. Future studies are required to establish the exact role of visfatin in the pathogenesis of GDM. (J. Endocrinol. Invest. 31: 610-613, 2008)

show abstract

“…Such a hypothesis is supported by the results of Haider et al [14], who demonstrated that glucose infusion (under clamp conditions) could increase visfatin concentrations. Recently, it has also been shown that subjects with established type 2 diabetes have significantly raised visfatin levels when compared with newly diagnosed type 2 diabetic subjects [15]. These findings are of interest, as GDM, like type 2 diabetes, is characterised by relative hyperglycaemia and the metabolic defects of insulin resistance [16].…”

Section: Discussionmentioning

confidence: 97%

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

et al. 2007

View full text Add to dashboard Cite

Aims/hypothesis Concentrations of visfatin are increased in insulin-resistant conditions, but the relationship between visfatin and insulin and/or insulin resistance indices in pregnancy remains unclear. Insulin resistance in pregnancy is further accentuated in women with gestational diabetes mellitus (GDM). Thus we assessed serum levels of visfatin in pregnant women with varying degrees of glucose tolerance. Materials and methods Fasting visfatin levels were measured at 28 weeks of gestation in 51 women divided according to their response to a 50-g glucose challenge test (GCT) and a 75-g OGTT: control subjects (n=20) had normal responses to both a GCT and an OGTT; the intermediate group (IG; n=15) had a false-positive GCT, but a normal OGTT; the GDM group (n=16) had abnormal GCTs and OGTTs. Results There were no age or BMI differences between analysed groups. Across the subgroups there was a progressive increase in glucose and insulin at 120 min of the OGTT (p<0.01). This was accompanied by an increase in visfatin, from 76.8±14.1 ng/ml in the control subjects, to 84.0±14.7 ng/ml in the IG group and 93.1±12.3 ng/ml in the GDM group (p<0.01 for GDM vs control subjects). There was a positive correlation between visfatin and fasting insulin (r=0.38, p=0.007) and insulin at 120 min of the OGTT (r=0.39, p=0.006). Conclusions/interpretation An increase in fasting visfatin, the levels of which correlate with both fasting and postglucose-load insulin concentrations, accompanies worsening glucose tolerance in the third trimester of pregnancy. However, the significance of these findings, and in particular the role of visfatin in the regulation of insulin sensitivity during pregnancy, remains to be elucidated.

show abstract

Serum Visfatin Increases With Progressive β-Cell Deterioration

Cited by 195 publications

References 20 publications

Visfatin Response to Glucose Is Reduced in Women With Gestational Diabetes Mellitus

Visfatin Response to Glucose Is Reduced in Women With Gestational Diabetes Mellitus

Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

Contact Info

Product

Resources

About